Histiocytosis Clinical Trials

6 recruiting

Histiocytosis Trials at a Glance

35 actively recruiting trials for histiocytosis are listed on ClinicalTrialsFinder across 6 cities in 18 countries. The largest study group is Phase 2 with 17 trials, with the heaviest enrollment activity in New York, Birmingham, and Washington D.C.. Lead sponsors running histiocytosis studies include Assistance Publique - Hôpitaux de Paris, Anna Raciborska, and West China Second University Hospital.

Browse histiocytosis trials by phase

Treatments under study

About Histiocytosis Clinical Trials

Looking for clinical trials for Histiocytosis? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Histiocytosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Histiocytosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 35 trials

Recruiting
Phase 2Phase 3

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Electra Therapeutics Inc.156 enrolled40 locationsNCT05416307
Recruiting
Phase 2

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recurrent Langerhans Cell HistiocytosisRefractory Langerhans Cell Histiocytosis
National Cancer Institute (NCI)48 enrolled117 locationsNCT05828069
Recruiting
Phase 2

Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)

Haemophagocytic Lymphohistiocytosis
Assistance Publique - Hôpitaux de Paris20 enrolled1 locationNCT05762640
Recruiting
Phase 1Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting
Phase 1Phase 2

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

Extranodal NK T Cell LymphomaHemophagocytic Lymphohistiocytosis (HLH)
Beijing Tongren Hospital25 enrolled1 locationNCT07525466
Recruiting
Phase 2

Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

Langerhans Cell Histiocytosis
Cook Children's Health Care System75 enrolled1 locationNCT06582745
Recruiting
Phase 2

Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients

Histiocytosis
Anna Raciborska12 enrolled1 locationNCT04943224
Recruiting
Phase 3

Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging

Histiocytosis
Anna Raciborska150 enrolled1 locationNCT04943211
Recruiting
Phase 2

Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

Histiocytosis
Anna Raciborska25 enrolled1 locationNCT04943198
Recruiting

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

Lymphohistiocytosis, HemophagocyticSecondary Hemophagocytic LymphohistiocytosisMacrophage Activation Syndrome+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled2 locationsNCT06339177
Recruiting
Not Applicable

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis

EBV-associated T/NK-cell Lymphoproliferative DiseasesRefractory/Relapsed EBV-related Hemophagocytic LymphohistiocytosisLetermovir
Beijing Children's Hospital80 enrolled1 locationNCT07488728
Recruiting

Project: Every Child for Younger Patients With Cancer

Malignant Solid NeoplasmNeuroendocrine NeoplasmCentral Nervous System Neoplasm+15 more
Children's Oncology Group75,000 enrolled278 locationsNCT02402244
Recruiting
Not Applicable

Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis

Langerhans Cell Histiocytosis (LCH)
West China Second University Hospital120 enrolled11 locationsNCT07431060
Recruiting
Not Applicable

Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions

Langerhans Cell Histiocytosis (LCH)
West China Second University Hospital62 enrolled11 locationsNCT07371182
Recruiting
Phase 2Phase 3

Golidocitinib Combined With Selinexor for CAEBVD

EBVLymphohistiocytosisCAEBV
Beijing Friendship Hospital28 enrolled1 locationNCT07369739
Recruiting
Phase 2Phase 3

Prospective Single-Arm Clinical Trial of GO Regimen for HLH.

Lymphohistiocytosis, Hemophagocytic
Beijing Friendship Hospital28 enrolled1 locationNCT07339345
Recruiting
Phase 4

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

Hemophagocytic Lymphohistiocytosis
The First Affiliated Hospital of Soochow University40 enrolled1 locationNCT07270835
Recruiting
Phase 3

A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])

Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
TJ Biopharma Co., Ltd.30 enrolled15 locationsNCT07208058
Recruiting
Phase 1

Q702 for the Treatment of Patients With Hematologic Malignancies

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic46 enrolled2 locationsNCT06712810
Recruiting
Phase 2

Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH

Langerhans Cell Histiocytosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT07187193